Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Gregory M. Weinhoff Sells 11,742 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 11,742 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $16.47, for a total value of $193,390.74. Following the sale, the insider now directly owns 159,782 shares in the company, valued at approximately $2,631,609.54. The trade was a 6.85 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Centessa Pharmaceuticals Trading Up 2.2 %

NASDAQ:CNTA opened at $16.96 on Thursday. The stock has a fifty day simple moving average of $16.80 and a 200 day simple moving average of $15.03. The firm has a market capitalization of $2.24 billion, a price-to-earnings ratio of -11.08 and a beta of 1.53. Centessa Pharmaceuticals plc has a 1-year low of $7.38 and a 1-year high of $18.97. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05. Sell-side analysts forecast that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Institutional Trading of Centessa Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after buying an additional 826 shares in the last quarter. GAMMA Investing LLC grew its stake in Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after acquiring an additional 1,509 shares in the last quarter. Quarry LP increased its holdings in shares of Centessa Pharmaceuticals by 47.8% in the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after purchasing an additional 3,108 shares during the period. XTX Topco Ltd purchased a new stake in shares of Centessa Pharmaceuticals in the second quarter worth approximately $148,000. Finally, Walleye Capital LLC acquired a new stake in shares of Centessa Pharmaceuticals during the third quarter worth approximately $187,000. 82.01% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CNTA has been the topic of a number of research reports. Guggenheim boosted their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals presently has an average rating of “Buy” and an average price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.